http://www.epitomebiosystems.com
Epitome Biosystems, Inc. develops and commercializes innovative protein measurement products and services to increase the productivity of drug discovery and development. The Company's products generate valuable information about the cell signaling network, which is a key interface for monitoring drug action and understanding disease. By delivering high-value information on cell signaling networks in a condensed time frame, Epitome's products and services are driving new research approaches for the development of drugs and diagnostics. The Company's products include profiling chips and assay kits, based on proprietary EpiTagâ„¢ technology, and mass spectrometry-based discovery partnerships (Q-SONARâ„¢). EpiTagâ„¢ profiling chips and multiplex assays provide highly specific, quantitative measurements of the cell signaling network. Q-SONARâ„¢ generates quantitative, broad-based analyses to elucidate cell network dynamics and connectivity, identify potential new targets/biomarkers and more comprehensively assess on- and off-target effects of drugs. Epitome's technology is validated, scaleable and can be applied broadly across the drug discovery and development continuum and translated to clinical biomarker applications. Epitome partners with pharmaceutical and biotechnology companies to deliver off-the-shelf products and customized solutions.
Bioleap is a leader in computational fragment-based drug design. The company's proprietary design technology and process successfully addresses one of the biggest problems in preclinical drug discovery: limited chemical diversity of compound libraries. Development collaborations span a broad spectrum of target proteins including: kinases, nuclear hormone receptors, metalloenzymes, and metalloproteases.
Artielle ImmunoTherapeutics' technology is focused on a new proprietary class of molecules known as Recombinant T cell receptor Ligands (RTLs) that can be tailored to treat a wide range of autoimmune diseases. Artielle has developed a lead compound for the treatment of multiple sclerosis, called RTL1000, which is in Phase 1 clinical trials and has received Orphan Drug status from the U.S. Food and Drug Administration. In addition to multiple sclerosis, Artielle is conducting research on other autoimmune diseases to which its platform technology is also applicable, such as rheumatoid arthritis, celiac disease and uveitis.
Chlorion Pharma, Inc. is a privately-held drug discovery company advancing next-generation CNS therapeutics to the clinic. Currently, Chlorion is focused on the development of small-molecule, disease-modifying compounds for the treatment of neuropathic pain, and subsequently for the treatment of epilepsy, bipolar disease and migraine. Chlorion's head office and research and development laboratories are located in Quebec City, Canada.
http://www.veracitybiotech.com
Veracity Biotechnology, LLC is a contract research organization (CRO) based in Frederick, MD devoted to the examination of drug resistance phenomenon and drug discovery for the hepatitis C virus (HCV). The assessment of HCV drug resistance through pre-clinical studies and the support of human clinical trial work is Veracity's principal focus. In addition, drug discovery and mechanism of action studies are also available. Our low overhead costs allow us to perform these studies at competitive rates. Results are provided to our clients in real-time, as they become available. For further information, please contact: Veracity Biotechnology LLC 5 South Wisner St. Frederick, MD 21701
Rhinopharma Ltd is a newly formed company dedicated to finding new drug treatments for rhinitis and other respiratory diseases. In the first phase of research strategy Rhinopharma is searching for new drugs for allergic rhinitis that can be rapidly brought to clinical trial. A longer term strategic goal of the company is to develop a range of therapeutic agents based on novel polysaccharide molecules. These molecules are biological "non-stick" agents with potential applications in inflammation, cell adhesion and tissue growth. The company plans to initially commercialize one such molecule as an anti-inflammatory agent for the treatment of allergic rhinitis in a relatively easy path to market, and then progress to research and development of agents based on active fragments of heparin and related natural and synthetic compounds. The company has access to powerful new synthetic and analytical chemical techniques which it will apply to modify heparin, and related molecules, to produce novel agents for the treatment of respiratory allergies, asthma and other inflammatory diseases. In the longer term, therapeutic applications also exist for arthritis, skin and bladder diseases. As part of this strategy the company also aims to exploit anti-adhesion molecules produced by echinoderms (starfish and related organisms) as improved therapeutic agents.
http://www.moleculardesign.com
MDI discovers, patents, and evaluates new drug candidates. MDI out licenses its proprietary drugs to pharmaceutical companies having the resources to develop them through the regulatory process and to market them aggressively. MDI does contract research in drug discovery and custom synthesis.
http://oneidathd.homestead.com
Oneida operates a centralised molecular testing service for a variety of genetic markers and disease-related mutations. As a front-end molecular testing service we also seek partnerships with other groups with clinically validated genetic markers looking to develop and commercialise their IP into clinical products. We currently offer the following portfolio of genetic tests using a state-of-the-art multiplex technology. For further information on each test and to open a clinical service account please fill in the enquiry form and we will contact you as soon as possible.
SignalChem offers a comprehensive discovery service which includes: gene cloning & expression of therapeutic 'targets', custom assay & antibody development and compound profiling for drug 'potency' & 'selectivity'. For further details, contact us with your specific needs. SignalChem offers a diverse range of cellular signaling products including: Active Kinases, Active Phosphatases, Unactive Enzymes, Assay Kits, Protein Substrates and much more. For a complete list of SignalChem's products, request a copy of SignalChem's 2006 catalog.
Amura is a structure-based drug discovery and pre-clinical development company dedicated to the invention of new technologies, innovative medicines and novel products for improving health. Amura's therapeutic focus is in the areas of osteoporosis, bone metastasis, autoimmunity (e.g. rheumatoid arthritis, osteoarthritis, psoriasis, etc.), chronic pain and malaria. Amura's AMcore scaffold is the premier chemical solution to cysteine peptidase inhibitor design. Amura products encompass its pre-clinical therapeutic programmes and intellectual property; which will be developed by strategic alliances with globally-recognised licensing partners.
http://www.sworddiagnostics.com
Sword Diagnostics is a leading-edge life sciences company created in response to the rapidly evolving needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.
Endocrine Pharmaceuticals (‘Endocrine') of North Hampshire, UK, is a life sciences company with expertise in the hormonal regulation of tissue mass and integrity. Additional areas of interest are fertility and lifespan. The company's discovery and research focus, micrin, is a naturally occurring mammalian hormonal inhibitor of tissue masses and an upholder of cellular integrity. Micrin prevents runaway tissue overgrowth and probably inhibits tumour formation and progression as well. Drug candidates related to micrin are under investigation for therapeutic benefit in a range of benign and malignant tissue overgrowth conditions affecting the pituitary, prostate, breast, heart, kidneys and other tissues, as well as in infertility. Endocrine optimises operational costs by conducting research through scientists in universities and research institutes in the UK and Australia. The company's chief executive is Dr John Hart, an endocrinologist by background with significant experience of drug development and exploitation. The company is privately held, by about 80 shareholders. Endocrine has a professionally constituted Board with technical, legal and commercial expertise, plus an internationally well-regarded Scientific Advisory Board, which includes notable leaders in the fields of endocrinology, physiology and biochemistry.
Xactagen produces and licenses gene expression reporter cells and other cell-based assays for drug discovery and development. Screening services with these assays are also available. Technology advances at Xactagen allow Xactagen scientists to introduce reporters into endogenous genes, such as those associated with human disease or drug responsiveness. In contrast to cloned promoters and reporters introduced ectopically into cells, Xactagen's endogenously regulated reporter cells provide highly faithful readouts of gene activity coupled with superior sensitivities. NEW: Xactagen announces its innovative AnyGeneTM reporter available for any gene in any human cell line at low introductory pricing . Throw away the catalog! You can specify any gene with any reporter in any cell line. AACR: Please visit us at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting on Thursday, October 25, 2007 in Poster Session C on Novel Assay Technology, Poster Abstract Number C94 .
MediBIC Group is a Japan-based company comprised of four business segments. The Biomarker Drug Discovery segment provides total support solution services, including development strategy planning consulting, data analysis and new-drug application support, to pharmacogenomics (PGx) tests. This segment also provides technology analytical services and software, as well as selling research support products. The Drug Discovery segment adds value to candidate compounds of genomic, advanced and general new drugs to acquire part of intellectual properties. The Investment and Incubation segment invests mainly in life science companies, and sells investees' products. The Others segment is engaged in the holding of seminars and forums for researchers. MediBIC has three subsidiaries. The Company acquired its affiliated company, Asia Private Equity Capital on October 1, 2008.
http://www.lifelikebiomatic.com
Lifelike Biomatic develops new drugs that act on a combination of multiple known targets of disease mechanisms. In our first year of existence, we have already discovered and advanced to a pre-clinical stage, a portfolio of drug candidates for the treatment of cognitive impairment resulting from certain neurodegenerative disorders, such as Alzheimer's disease. Our scientists have shown that drugs which act on multiple targets have higher efficacy at lower doses, resulting in an improved safety-efficacy profile. Our discovery approach is driven by a patented simulation-based platform that integrates the complex network of targets of disease mechanisms and identifies optimal patterns of synergistic physiological activities.
http://www.criticaloutcome.com
Critical Outcome Technologies Inc. (COTI) is a biotechnology company focused on applying its computer-based technology, CHEMSAS, to identify, profile and optimize commercially viable drug candidates at the earliest stage of pre-clinical drug development. Using CHEMSAS, COTI is developing libraries of 6 to 10 small molecules as drug candidates for specific therapeutic targets in diseases that have high morbidity and mortality. Following synthesis and completion of a core group of confirmatory in-vitro and in-vivo tests, COTI plans to license these molecules to pharmaceutical partners for further drug development and human trials. Libraries in various stages of development include small cell lung cancer, adult acute leukemia, colorectal cancer and other cancers, human immunodeficiency virus (HIV) integrase inhibitors and secretase inhibitors for the treatment of Alzheimer’s disease. On May 1, 2008, COTI amalgamated with its subsidiary, 3015402 Ontario Inc., operating as DDP Therapeutics. (Source: ARS)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory